Top 10 of the world's best selling drugs in 2025: BMS takes three places, Humira falls to the sixth place

Recently, global data, a well-known global market research institution, released the list of the top 10 best selling drugs in the world in 2025 It is predicted that keytruda, an immunooncology drug of MSD, will become the best-selling drug in 2023, with a sales volume of 22.2 billion US dollars in 2025 Keytruda has become the most important product of MSD since it was approved by FDA in 2015 Up to now, keytruda has been approved for more than 20 tumor indications in the United States With the largest immunooncology project in the industry, MSD is continuing to expand new indications and markets worldwide Keytruda's sales reached $7.973 billion in the first nine months of this year, up 58.8% from the same period last year No 2 on the list is BMS / Pfizer's oral anticoagulant eliquis, which will continue to grow strongly with sales expected to reach $18.7 billion in 2025 No 3 on the list is Revlimid, a new heavyweight immunomodulator with sales expected to reach $12.4 billion in 2025, but the drug will also be affected by generic drugs In the US, Revlimid is expected to enter the market in 2022 No 4 on the list is opdivo of BMS, which is expected to generate $12 billion in sales in 2025 The drug is keytruda's main competitor in the field of immunooncology Opdivo's sales in the first nine months of this year were $5441 million, up 10% from the same period last year At present, the BMS new base M & A is in progress, and Revlimid will be owned by BMS after the completion of the M & A This also means that in the list of top 10 best selling drugs in the world in 2025, BMS will hold three products - eliquis, Revlimid and opdivo, and the total sales will reach 43.1 billion US dollars in 2025 No 5 on the list is imbruvica, a Btk inhibitor from Johnson & Johnson / Aberdeen, whose sales are expected to reach $11.9 billion in 2025 Since its launch in November 2013, the drug has been approved for up to 10 therapeutic indications in 6 disease areas, including 5 kinds of B-cell blood cancer and chronic graft-versus-host disease At present, both sides are promoting the huge clinical development project of imbruvica No 6 on the list is the flagship product Humira, which is currently the best-selling drug in the world In Europe, sales of Humira declined significantly due to the competition of bio generic drugs With the full development of bio generic competition in the U.S market in 2023, Humira is bound to give way, and its sales volume is expected to decline to $10.3 billion in 2025 The seventh on the list is Biktarvy, a three in one HIV drug of Geely science, with sales expected to reach $10 billion in 2025 The drug was approved by the US FDA in February 2018 At present, the indications are: as a complete treatment scheme, it is used for the first-line and second-line treatment of HIV-1 infected adults and children (weight ≥ 25 kg) Since its IPO, biktarvy's sales have risen sharply, exceeding $1 billion in the first year Sales of the drug in the first nine months of this year reached US $3.168 billion, an increase of 423% compared with us $606 million in the same period last year Pfizer's breast cancer drug ibrance, Johnson & Johnson's immunologic biological agent stellara and Lilly's hypoglycemic drug trulicity rank 8-10 on the list The sales volume in 2025 is estimated to be $9.0 billion, $7.5 billion and $7.2 billion respectively Ibrance is the first listed and best-selling CDK4 / 6 inhibitor in the world, with sales of US $4.118 billion in 2018 Stellara is a core product of Johnson & Johnson in the field of autoimmune diseases The drug was first launched in Canada in December 2008, with sales of $5.3 billion in 2018 However, its patent protection in the United States and the European Union will expire in September 2023 and July 2024, respectively Trulicity, a weekly glucagon like peptide-1 receptor agonist, was approved for marketing in September 2014, with sales of $3.2 billion in 2018 Reference source: the best selling drugs of the next 5 years